A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Andecaliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Mar 2017 This trial has been completed in Germany (end date: 2016-12-22).
    • 13 Jan 2017 This trial has been completed in Spain (end date: 2016-12-22).
    • 09 Jan 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top